Table 1.

HIF/VEGF/DC therapy in several cancers

Cancer	Therapy	Common Drug	Impact	Clinical Course	Ref
Multiple Myeloma	Anti-VEGF	Bortezomib	Improve overall survival	FDA approved	[80,110]
	HIF inhibitor	EZN-2968	Reduces cancer cell viability	Pre-clinical trail	[81]
	DC vaccine	SC-DC vaccine	Induce antitumor response	Clinical trail	[83,111]
Colorectal Cancer	Anti-VEGF	Bevacizumab	Acquired resistance develop	FDA approved	[84,112]
	HIF inhibitor	DNMT inhibitors: zebularine	Overcome oxaliplatin resistance	Pre-clinical	[85]
	DC vaccine	/	Enhance immune	Clinical trail	[88,89]
			response;
			Improve survival
Prostate Cancer	Anti-VEGF	Bevacizumab, Sutent	Improve survival	Clinical trail	[90,113]
	HIF inhibitor	Acriflavine	Potent effects	Pre-clinical trail	[91,114]
	DC vaccine	Provenge	Induce immune response	FDA approved	[115]
Lung Cancer	Anti-VEGF	Bevacizumab	Improve progression free survival	FDA approved	[93,94,116]
			Improve survival
	HIF inhibitor	SOCS3	Inhibit proliferation and angiogenesis	Pre-clinical trail	[95]
	DC vaccine	/	Induce immune response;	Clinical trail	[97]
			Improve survival
Renal Cancer	Anti-VEGF	Axitinib, Sutent	Improve survival	FDA approved	[103,117]
	HIF inhibitor	MK-6482	Greater activity than sutent	FDA approved	[105,106]
	DC vaccine	HybriCell	Induce immune response with well torlerance	FDA approved	[104]